English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Uvajanje Novih Farmacevtskih Storitev ob Prehodu na Centralizirano Pripravo Protitumorskih Zdravil Uvod: Protitumorska zdravila uvrščamo med zdravila z velikim tveganjem. Pri zagotavljanju kakovosti, varnosti in učinkovitosti uporabe protitumorskih zdravil vloga farmacevta ne sme biti omejena le na njihovo pripravo. S prispevkom želimo predstaviti vpeljavo farmacevtske storitve pregled predpisa kemoterapije v klinično prakso in z analizo zabeleženih ukrepov prikazati njene koristi. Metode: Raziskava je potekala v Bolnišnici Golnik KOPA, kjer protitumorska zdravila pripravljajo centralizirano. Uporabili so metode za vpeljavo storitve pregled predpisa kemoterapije. Po njeni vpeljavi so farmacevti leta 2009 v petmesečnem obdobju beležili ukrepe med njenim izvajanjem in jih analizirali. Rezultati: Pregled predpisa kemoterapije s strani farmacevta smo vpeljali v rutinsko klinično prakso in ob tem opredelili njegove naloge in dolžnosti. V opazovanem obdobju je bilo vključenih 506 naročil kemoterapije, pri njihovem pregledu pa je pet farmacevtov zabeležilo 211 ukrepov. Velik delež ukrepov dokazuje, da je vpeljana storitev koristna. Ukrepi so vključevali protitumorska zdravila (31 %), antiemetike (41 %) in druga zdravila v podpornem zdravljenju (12 %). Do neskladij je prišlo pri kategorijah »odmerek in režim odmerjanja« (64 %), »izbira zdravila« (21 %) in »administrativna« kategorija (14 %). Najbolj pogoste kategorije in podkategorije z zaznanimi neskladji kažejo, katera področja je potrebno izboljšati. Zdravniki so uresničili večino predlaganih ukrepov (76 %), kar potrjuje potrebo in smiselnost predlaganih intervencij tudi z zdravniškega zornega kota. Zbrani podatki zaenkrat ne vsebujejo informacij o kliničnem pomenu predlaganih uresničenih in neuresničenih ukrepov za bolnikovo zdravstveno oskrbo. Zaključek: Velik delež intervencij, opisan v tej študiji, potrjuje, kako pomembno je, da v onkološko dejavnost vključimo farmacevtova klinična znanja, da bi zagotavili visoko kakovost njenih storitev. Implementing new clinical pharmacy services parallel to the introduction of centralized preparation of anti-cancer drugs Introduction: Anti-cancer drugs belong to a group of high-risk medications. In guaranteeing the quality, safety and efficacy of these drugs, pharmacists' role should not be restricted to overseeing their preparation. This study describes the implementation of a new pharmacy service - chemotherapy prescription screening - and evaluates its benefits by analysing the recorded interventions. Methods: The study was conducted in a Slovene teaching hospital with centralized chemotherapy preparation, in which methods to implement chemotherapy prescription screening were introduced. After this service had been implemented, the performed interventions were recorded over a five-month period in 2009. Results: Chemotherapy prescription screening by pharmacists was integrated into routine clinical practice, and pharmacists' responsibilities and duties were defined. During the study period, 506 cancer prescriptions were reviewed by five pharmacists, who recorded 211 interventions. The high rate of interventions emphasizes the role that pharmacists play in oncology services. The interventions involved cancer drugs (31%), antiemetics (41%) and other support care drugs (12%). The identified problems were related to the following categories: "dose, frequency and regimen" (64%), "drug selection" (21%) and "administrative" (14%). Clinicians accepted most pharmacists' recommendations (76%), thereby confirming the need for the proposed interventions also from a medical point of view. However, the study provides no information on the clinical significance of the recorded interventions, whether accepted or not. Conclusion: The high rate of interventions recorded in this study stresses the importance of integrating pharmacists' clinical roles into oncology services in order to maintain high quality standards of cancer treatment.